査読有
doi：10.1016/j.clnesp.2026.105040
PubMed No.：42624401
2025 Impact Factor：3.4
種類：原著
誌名：Clinical Nutrition ESPEN
発行年月：2026年8月
巻号頁：in press
論題：Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy
著者：Maho Egusa, Issei Saeki, Yasuto Takeuchi, Shigeo Shimose, Takanori Ito, Joji Tani, Ryu Sasaki, Kyo Sasaki, Takeshi Hatanaka, Takaya Suzuki, Rintaro Kobayashi, Satoru Kakizaki, Norikazu Tanabe, Sohji Nishina, Hisamitsu Miyaaki, Hideki Kobara, Hiroki Kawashima, Takumi Kawaguchi, Motoyuki Otsuka, Takahiro Yamasaki, Taro Takami; Hepatology InVestigator Experts in Japan (HIVE-J) Study Group
